Skip to main content

Table 2 Preselected c-AMP dependent genes found to be significantly differentially expressed in sputum cells of COPD patients after treatment with tanimilast 1600 μg/day or 3200 μg/day relative to standard of care [inhaled corticosteroid (ICS) plus dual bronchodilators (LABA + LAMA)]

From: The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

ID

Gene symbol

Gene title

Entrez gene

Fold change (tanimilast 1600 μg/day vs. placebo)

p value (tanimilast 1600 μg/day vs. placebo)

Fold change (tanimilast 3200 μg/day vs. placebo)

p value (tanimilast 3200 μg/day vs. placebo)

207901_at

IL12B

Interleukin 12B

3593

− 2.23

4.37E−06*

− 1.86

2.83E−04*

204057_at

IRF8

Interferon regulatory factor 8

3394

− 0.12 (ns)

0.12

− 1.07

0.20 (ns)

210029_at

IDO1

Indoleamine 2,3-dioxygenase 1

3620

−1.24

0.2538 (ns)

1.25

0.2207 (ns)

201108_s_at

THBS1

Thrombospondin 1 (TSP1)

7057

1.23

4.44E−02*

1.54

3.04E−05*

212171_x_at

VEGFA

Vascular endothelial growth factor A

7422

1.19

1.44E−02*

1.23

3.39E−03*

1557285_at

AREG

Amphiregulin

374

2.05

1.86E−04*

2.89

1.31E−07*

203888_at

THBD

Thrombomodulin (CD141)

7056

1.12

5.15E−03*

1.12

4.14E−03

  1. *P < 0.05